TAPIMMUNE INC. (NASDAQ:TPIV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On April 27, 2017, The Company and Dr. Bonfiglio have entered
into a Separation and Release agreement (the Separation
Agreement) to which Dr. John Bonfiglio resigned as President,
Chief Operating Officer and director of the Company to pursue
other opportunities. Dr. Bonfiglios resignation was not due to
any disagreement with the Company on any matter related to its
operations, policies or practices.
The Separation Agreement provides for a customary release by Dr.
Bonfiglio of claims against the Company and a mutual
non-disparagement covenant. Dr. Bonfiglio is also obligated to
comply with various restrictive covenants, including a
non-compete, non-solicitation and protection of the Companys
confidential information. Any disputes arising under the
Separation Agreement will be resolved by binding arbitration. The
Separation Agreement is subject to revocation through May 4,
2017, and the Separation Agreement will not become effective and
enforceable until the revocation period expires.
The Companys Chief Executive Officer, Dr. Glynn Wilson, was
appointed to serve as the President of the Company and the size
of the Companys board of directors was reduced from seven members
to six members.
A copy of the April 28, 2017 press release announcing the Change
in Management and Board of Directors is attached to this report
as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated April 28, 2017 |
About TAPIMMUNE INC. (NASDAQ:TPIV)
TapImmune Inc. is an immuno-oncology company. The Company specializes in the development of peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. The Company is engaged in developing vaccines that target candidate breast cancers, colorectal cancers, ovarian cancers and non-small cell lung cancers. The Company combines a set of licensed technologies, including peptide antigen technologies and deoxyribonucleic acid (DNA) expression technologies that improve the ability of the cellular immune system to recognize and destroy diseased cells. The Company’s core technology platforms include TPIV 100/110, a vaccine for the treatment of Human Epidermal Growth Factor receptor 2 (HER2)/neu+ breast cancer that over-expresses HER2/neu; TPIV 200, a vaccine for treating breast and ovarian cancers that over-express Folate Receptor Alpha, and DNA expression vaccine technology (Polystart) for further treating various cancers or infectious disease. TAPIMMUNE INC. (NASDAQ:TPIV) Recent Trading Information
TAPIMMUNE INC. (NASDAQ:TPIV) closed its last trading session up +0.09 at 4.26 with 39,187 shares trading hands.
